Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb, Meso Scale Discovery Developing Assays for Alzheimer's Research

NEW YORK (GenomeWeb News) – Bristol-Myers Squibb and Meso Scale Discovery today announced a deal to develop assays for use in Alzheimer's disease research.

The assays, which will measure biomarkers in cerebrospinal fluid, will be based on the Meso Scale Discovery Multi-Array technology platform. The technology consists of proprietary patterned arrays and electrochemiluminescence detection and enables "large number of measurements with exceptional sensitivity, wide dynamic range, and convenience," according to Meso Scale Discovery, a division of Meso Scale Diagnostics.

Meso Scale Discovery, based in Gaithersburg, Md., plans to commercialize the assays for Alzheimer's research and drug development in the second quarter.

"These assays could provide the Alzheimer's disease research community with an important tool to help advance understanding of this complex and devastating disease and may lead to advances in the diagnosis and treatment of Alzheimer's disease," Jane Tiller, vice president of global clinical research for Bristol-Myers Squibb, said in a statement.

Financial and other terms were not disclosed.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.